SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications (SYTHROM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04539678 |
|
Recruitment Status :
Recruiting
First Posted : September 7, 2020
Last Update Posted : September 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Among the etiologies of thrombosis, myeloproliferative neoplasia (MPN) is quite rare but should be investigated in case of thrombosis of atypical localization (digestive or cerebral) or in the context of recurrent idiopathic thrombosis in a young subject. Thrombosis could reveal an underlying MPN through the identification of a JAK2 V617F mutation. Rarely, MPN with thrombotic complications present with normal complete blood count(CBC). In case of a MPN with a thrombotic event but without CBC abnormality, anti-thrombotic treatment is recommended. But there is no recommendation for the indication of cytoreductive therapy and the clinician's decision is often empirical.
One of the major complications of for essential thrombocythemia (ET) or polycythemia vera (PV) is thrombosis and an age over 60 is a major risk factor. The treatment of thrombosis associated with TE or PV is based on recommendations the main therapeutic objective of which is to reduce the thrombotic risk. The combination of a cytoreducing agent and antithrombotic treatment is thus proposed in high-risk patients. The efficacy of this management is monitored by assessing CBC with the objective of normalization at <400 G/L of platelets for ET patients and <45% hematocrit in case of PV.
The absence of abnormal CBC makes it difficult to justify cytoreduction. The benefit of such a therapy in this context has not been clinically demonstrated. If a cytoreductive therapy is initiated, no biological parameters are available to assess the response to treatment.
The objective of this observational study is to evaluate the incidence of recurrence of thrombosis in patients whose thrombotic event revealed an underlying MPN with normal CBC. A comparison of groups treated or not with cytoreductive agents will be performed. Longitudinal monitoring of the patients will provide a better understanding of the nature and kinetics of hematological changes in these patients.
| Condition or disease |
|---|
| Thrombotic Patients Diagnosis of Myeloproliferative Neoplasia Impact of Treatment With Cytoreducing Agent |
| Study Type : | Observational |
| Estimated Enrollment : | 200 participants |
| Observational Model: | Cohort |
| Time Perspective: | Retrospective |
| Official Title: | Retrospective and Prospective Multicenter Study Evaluating the Impact of Treatment With Cytoreducing Agents on the Recurrence of Thrombosis in Thrombotic Patients With a Diagnosis of Myeloproliferative Neoplasia and Normal Blood Counts - a FIM Study |
| Actual Study Start Date : | May 21, 2019 |
| Estimated Primary Completion Date : | May 21, 2023 |
| Estimated Study Completion Date : | May 21, 2023 |
- Cumulative incidence of recurrence of thromboembolic events after the initial thrombosis leading to the diagnosis of MPN [ Time Frame: 24 months follow-up ]The diagnosis of thromboembolic events must be confirmed by imaging
- Cumulative incidence of hematological progression to essential thrombocythemia, polycythemia vera, secondary myelofibrosis or acute transformation [ Time Frame: 24 months follow-up ]Hematological progression criteria will be based on the WHO classification
- Cumulative incidence of recurrence of thromboembolic events according to the type and duration of anticoagulant or anti-aggregant treatment [ Time Frame: 24 months follow-up ]The diagnosis of thromboembolic event must be confirmed by imaging
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria :
- Adult ≥18 years old
- Diagnosis of a deep arterial or venous thrombotic event verified by imaging (Doppler or CT scan)
- Diagnosis of MPN with normal CBC according to WHO 2017 criteria characterized by the detection of a molecular abnormality JAK2V617F mutation (regardless of allelic load), CALR or MPL and/or a bone marrow biopsy with abnormalities in favor of MPN.
- Normal blood cell count not suggestive of polycythemia vera (hematocrit<48% and hemoglobin<16g/dL for women; hematocrit<49% and hemoglobin<16.5g/dL for men), essential thrombocythemia (platelets<450 G/L) nor myelofibrosis (white blood cell count<11 G/L, no anemia or erythromyelemia associated with splenomegaly) at the time of the thrombotic event.
Exclusion Criteria :
- Minors (<18 years of age)
- Microcirculation disorders (erythromelalgia, headaches, paresthesia, ischemia of the extremities)
- Superficial or deep arterial or venous thrombosis NOT verified by imaging
- Diagnosis or history of TE, PV or myelofibrosis at time of first thrombotic event
- Diagnosis of mixed myelodysplastic/myeloproliferative syndrome
- Diagnosis of unclassifiable MPN with excess blasts at the onset or signs of myelodysplasia as defined by the WHO 2017 classification
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04539678
| Contact: Yannick LE BRIS, PhD | 330240084630 | yannick.lebris@chu-nantes.fr |
| France | |
| Nantes University Hospital | Recruiting |
| Nantes, Loire-Atlantique, France, 44093 | |
| Contact: Yannick LE BRIS, Phd 02 40 08 46 30 yannick.lebris@chu-nantes.fr | |
| Contact: Annick COULON 02.53.48.28.35 annick.coulon@chu-nantes.fr | |
| Principal Investigator: | Yannick LE BRIS, PhD | Nantes University Hospital |
| Responsible Party: | Nantes University Hospital |
| ClinicalTrials.gov Identifier: | NCT04539678 |
| Other Study ID Numbers: |
RC20_0141 |
| First Posted: | September 7, 2020 Key Record Dates |
| Last Update Posted: | September 9, 2021 |
| Last Verified: | September 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Thrombosis Myeloproliferative neoplasm Hydroxyurea Interferon |
|
Neoplasms Disease Pathologic Processes |